The ascendancy of Viagra and its impact on the pharmaceutical landscape presents a complicated question for shareholders. While the first sales data were astounding, the patent has lapsed, leading to a deluge of copycat alternatives that are reducing earnings. Moreover, the sector is facing issues related to aging trends and shifting healthcare reg